Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

This study compared the carbon footprint of SC and IV administration using pertuzumab/trastuzumab as a case example. A Life Cycle Assessment was conducted to compare the environmental impacts of IV ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Most of my life I have been pretty stoic about getting injections or blood draws and even as a child I wasn’t bothered by syringes or needles. Now the thought ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...

Alteogen will receive an upfront payment of $20 million, with another $280 million on offer from Daiichi Sankyo if the new formulation of Enhertu (trastuzumab ... versions of IV Enhertu, which ...

The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...